Literature DB >> 26824664

Hypertension and Diabetic Nephropathy.

Jeppe Skov, Jens Sandahl Christiansen, Per Løgstrup Poulsen.   

Abstract

Diabetic nephropathy (DN) is a major complication of both type 1 and type 2 diabetes. DN is the most common cause of end-stage renal disease, and it markedly enhances the risk of cardiovascular events. An elevated urinary albumin excretion rate, increased blood pressure (BP), and a continual loss of renal function are characteristics of DN. Screening for microalbuminuria is central to diabetes care, and antihypertensive agents are used for the primary prevention and treatment of DN. Angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers play central roles and have protective properties beyond their BP-lowering effects. BP control in relation to DN is the main focus of this review, but tight control of the glucose level is equally important. There is an unmet need for new treatment options, and while a few promising candidates exist, their roles in clinical practice have not yet been determined.
© 2016 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26824664     DOI: 10.1159/000439393

Source DB:  PubMed          Journal:  Endocr Dev        ISSN: 1421-7082


  2 in total

1.  Synergistic Interaction of Hypertension and Diabetes in Promoting Kidney Injury and the Role of Endoplasmic Reticulum Stress.

Authors:  Zhen Wang; Jussara M do Carmo; Nicola Aberdein; Xinchun Zhou; Jan M Williams; Alexandre A da Silva; John E Hall
Journal:  Hypertension       Date:  2017-03-27       Impact factor: 10.190

2.  Luteolin attenuates angiotensin II‑induced renal damage in apolipoprotein E‑deficient mice.

Authors:  Ying-Shu Liu; Qin Yang; Shen Li; Lan Luo; Hong-Yang Liu; Xin-Yu Li; Zheng-Nan Gao
Journal:  Mol Med Rep       Date:  2020-12-23       Impact factor: 2.952

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.